Rize Oncology Inc.
RIZE
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 26.45% | 25.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.95% | 15.30% | |||
| Operating Income | -31.95% | -15.30% | |||
| Income Before Tax | -32.25% | -19.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.25% | -19.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.25% | -19.39% | |||
| EBIT | -31.95% | -15.30% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -33.33% | -17.86% | |||
| Normalized Basic EPS | -28.57% | -23.53% | |||
| EPS Diluted | -33.33% | -17.86% | |||
| Normalized Diluted EPS | -28.57% | -23.53% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||